Haemonetics Stock Analysis

HAE Stock  USD 64.24  0.99  1.52%   
Haemonetics is overvalued with Real Value of 56.67 and Target Price of 110.8. The main objective of Haemonetics stock analysis is to determine its intrinsic value, which is an estimate of what Haemonetics is worth, separate from its market price. There are two main types of Haemonetics' stock analysis: fundamental analysis and technical analysis.
The Haemonetics stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Haemonetics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Haemonetics Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The book value of Haemonetics was currently reported as 18.05. The company has Price/Earnings To Growth (PEG) ratio of 1.08. Haemonetics had not issued any dividends in recent years. The entity had 2:1 split on the 3rd of December 2012. Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people. To learn more about Haemonetics call Ronald Gelbman at 781 848 7100 or check out https://www.haemonetics.com.

Haemonetics Quarterly Total Revenue

348.54 Million

Haemonetics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Haemonetics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Haemonetics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Haemonetics generated a negative expected return over the last 90 days
Haemonetics is unlikely to experience financial distress in the next 2 years
Over 99.0% of the company shares are owned by institutional investors
Latest headline from simplywall.st: Is Haemonetics Using Too Much Debt

Haemonetics Upcoming and Recent Events

8th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

Haemonetics Largest EPS Surprises

Earnings surprises can significantly impact Haemonetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2003-07-24
2003-06-300.10.110.0110 
1999-10-28
1999-09-300.10.110.0110 
1999-01-29
1998-12-310.10.09-0.0110 
View All Earnings Estimates

Haemonetics Environmental, Social, and Governance (ESG) Scores

Haemonetics' ESG score is a quantitative measure that evaluates Haemonetics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Haemonetics' operations that may have significant financial implications and affect Haemonetics' stock price as well as guide investors towards more socially responsible investments.

Haemonetics Thematic Classifications

In addition to having Haemonetics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Obamacare Repeal Idea
Obamacare Repeal
Large healthcare related equities associated with Obamacare
Baby Boomer Prospects Idea
Baby Boomer Prospects
Mega stocks, funds and ETFs that tend to appeal to people considering retirement from the work force

Haemonetics Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Dimensional Fund Advisors, Inc.2024-12-31
992.2 K
Btim Corp2024-12-31
915.7 K
Schroder Investment Management Group2024-12-31
894.5 K
Sg Capital Management, Llc2024-12-31
878.8 K
Westfield Capital Management Company, L.p.2024-12-31
805.9 K
Allspring Global Investments Holdings, Llc2024-12-31
801 K
Fmr Inc2024-12-31
796.7 K
Fisher Asset Management, Llc2024-12-31
711.8 K
Goldman Sachs Group Inc2024-12-31
695.3 K
Blackrock Inc2024-12-31
6.2 M
Vanguard Group Inc2024-12-31
5.2 M
Note, although Haemonetics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Haemonetics Market Capitalization

The company currently falls under 'Mid-Cap' category with a total capitalization of 3.28 B.

Haemonetics Profitablity

The company has Net Profit Margin of 0.09 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.19 %, which entails that for every 100 dollars of revenue, it generated $0.19 of operating income.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.05  0.08 
Return On Capital Employed 0.07  0.06 
Return On Assets 0.04  0.07 
Return On Equity 0.06  0.10 

Management Efficiency

Haemonetics has Return on Asset of 0.0633 % which means that on every $100 spent on assets, it made $0.0633 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1406 %, implying that it generated $0.1406 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Haemonetics' Return On Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.10, whereas Return On Capital Employed is forecasted to decline to 0.06. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 99.2 M, whereas Other Assets are forecasted to decline to 1.09.
Last ReportedProjected for Next Year
Book Value Per Share 14.26  7.57 
Tangible Book Value Per Share 7.29  5.03 
Enterprise Value Over EBITDA 25.70  26.99 
Price Book Value Ratio 5.13  2.79 
Enterprise Value Multiple 25.70  26.99 
Price Fair Value 5.13  2.79 
Enterprise Value1.4 B1.5 B
Evaluating the management effectiveness of Haemonetics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Haemonetics Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Operating Margin
0.1897
Profit Margin
0.0947
Beta
0.429
Return On Assets
0.0633
Return On Equity
0.1406

Technical Drivers

As of the 20th of March, Haemonetics retains the Risk Adjusted Performance of (0.11), market risk adjusted performance of (0.67), and Standard Deviation of 2.58. Haemonetics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Haemonetics standard deviation, maximum drawdown, kurtosis, as well as the relationship between the information ratio and potential upside to decide if Haemonetics is priced fairly, providing market reflects its last-minute price of 64.24 per share. Given that Haemonetics has information ratio of (0.11), we strongly advise you to confirm Haemonetics's regular market performance to make sure the company can sustain itself at a future point.

Haemonetics Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Haemonetics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Haemonetics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Haemonetics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Haemonetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Haemonetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Haemonetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Haemonetics Outstanding Bonds

Haemonetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Haemonetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Haemonetics bonds can be classified according to their maturity, which is the date when Haemonetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Haemonetics Predictive Daily Indicators

Haemonetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Haemonetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Haemonetics Corporate Filings

8K
3rd of March 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
6th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
14th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
3rd of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
3rd of December 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
14th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
13A
12th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
8th of November 2024
An amended filing to the original Schedule 13G
ViewVerify

Haemonetics Forecast Models

Haemonetics' time-series forecasting models are one of many Haemonetics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Haemonetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Haemonetics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Haemonetics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Haemonetics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Haemonetics. By using and applying Haemonetics Stock analysis, traders can create a robust methodology for identifying Haemonetics entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.07  0.12 
Operating Profit Margin 0.06  0.06 
Net Profit Margin 0.05  0.08 
Gross Profit Margin 0.46  0.57 

Current Haemonetics Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Haemonetics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Haemonetics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
110.8Strong Buy10Odds
Haemonetics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Haemonetics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Haemonetics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Haemonetics, talking to its executives and customers, or listening to Haemonetics conference calls.
Haemonetics Analyst Advice Details

Haemonetics Stock Analysis Indicators

Haemonetics stock analysis indicators help investors evaluate how Haemonetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Haemonetics shares will generate the highest return on investment. By understating and applying Haemonetics stock analysis, traders can identify Haemonetics position entry and exit signals to maximize returns.
Begin Period Cash Flow284.5 M
Total Stockholder Equity960 M
Property Plant And Equipment Net366.6 M
Cash And Short Term Investments178.8 M
Cash178.8 M
50 Day M A68.2212
Net Interest Income-13 M
Total Current Liabilities300.4 M
Forward Price Earnings12.9366
Investments-322.4 M
Interest Expense13 M
Stock Based Compensation28.3 M
Long Term Debt797.6 M
Common Stock Shares Outstanding51.4 M
Tax Provision34.3 M
Quarterly Earnings Growth Y O Y0.213
Free Cash Flow115.5 M
Other Current Assets66.3 M
Accounts Payable73.4 M
Net Debt629 M
Other Operating Expenses1.1 B
Non Current Assets Total1.4 B
Liabilities And Stockholders Equity2.2 B
Non Currrent Assets Other81.1 M

Complementary Tools for Haemonetics Stock analysis

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum